Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. (vol 59, 1867, 2023)

被引：0
|
作者：
Arce-Huamani, Miguel A. [1 ,2 ]
Barboza, Joshuan J. [3 ]
Martinez-Herrera, Jose Fabian [2 ,4 ]
Torres-Roman, J. Smith [2 ,5 ]
Maguina, Jorge L. [1 ]
机构：
[1] Univ Cientif del Sur, Fac Ciencias Salud, Lima 15067, Peru
[2] Univ Cientif del Sur, Canc Res Networking, Lima 15067, Peru
[3] Univ Norbert Wiener, Ctr Invest Epidemiol & Med Basada Evidencia, Lima 13007, Peru
[4] Med Ctr Amer British Cowdray, Canc Ctr, Mexico City 01120, Mexico
[5] Latin Amer Network Canc Res LAN CANC, Lima 11702, Peru
来源：
MEDICINA-LITHUANIA | 2024年 / 60卷 / 01期
关键词：
D O I：
10.3390/medicina60010134
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis
    Arce-Huamani, Miguel A.
    Barboza, Joshuan J.
    Martinez-Herrera, Jose Fabian
    Torres-Roman, J. Smith
    Maguina, Jorge L.
    MEDICINA-LITHUANIA, 2023, 59 (10):
  • [2] A systematic review of apixaban in prevention and treatment of cancer-associated venous thromboembolism
    Caputo, Ryan
    Pyle, Jacqueline
    Kuriakose, Philip
    Lekura, Jona
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2021, 61 (05) : E26 - E38
  • [3] Apixaban versus low molecular weight heparin in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis
    Amin, Anam
    Naeem, Muhammad Omar
    Amin, Laraib
    Khaliq, Saad Ul
    Ahmad, Athar
    Vohra, Rimsha Rahim
    Jawad, Sayed
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (08): : 4675 - 4683
  • [4] Efficacy and Safety of Apixaban versus Low Molecular Weight Heparin for the Treatment of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis
    Shrestha, Abhigan Babu B.
    Mainali, Nischal
    Shrestha, Shubham
    Jaiswal, Vikash
    Shrestha, Sajina
    Adhikari, Ashok
    Chapagain, Sanskriti
    Shrestha, Shumneva
    Sedhai, Yub Raj
    Rijal, Rishikesh
    Karki, Bikash
    Bhattarai, Suju
    Nuruzzaman, Md.
    CIRCULATION, 2023, 148
  • [5] Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies
    Fredman, Danielle
    McNeil, Rotem
    Eldar, Ofir
    Leader, Avi
    Gafter-Gvili, Anat
    Avni, Tomer
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (03) : 453 - 465
  • [6] Efficacy and safety of rivaroxaban versus apixaban for venous thromboembolism: A systematic review and meta-analysis of observational studies
    Danielle Fredman
    Rotem McNeil
    Ofir Eldar
    Avi Leader
    Anat Gafter-Gvili
    Tomer Avni
    Journal of Thrombosis and Thrombolysis, 2024, 57 : 453 - 465
  • [7] Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis
    Ning, Haoyu
    Yang, Nana
    Ding, Yuanyuan
    Chen, Haokun
    Wang, Lele
    Han, Yuxuan
    Cheng, Gang
    Zou, Meijuan
    MEDICINA CLINICA, 2023, 160 (06): : 245 - 252
  • [8] Direct oral factor Xa inhibitors for the treatment of acute cancer-associated venous thromboembolism: A systematic review and network meta-analysis.
    Fuentes, Harry E.
    McBane, Robert
    Wysokinski, Waldemar
    Tafur, Alfonso Javier
    Loprinzi, Charles L.
    Murad, M. Hassan
    Bin Riaz, Irbaz
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Efficacy and Safety of Rivaroxaban Versus Apixaban in Patients with Venous Thromboembolism: A Systematic Review and Meta-Analysis of Observational Studies
    Fredman, Danielle
    McNeil, Rotem
    Eldar, Ofir
    Leader, Avi
    Gafter-Gvili, Anat
    Avni, Tomer
    BLOOD, 2022, 140 : 5664 - 5665
  • [10] Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism
    Kimpton, Miriam
    Carrier, Marc
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (04) : 313 - 320
12345